JP2018533954A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533954A5
JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
expression
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533954A (ja
JP6751142B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/077383 external-priority patent/WO2017081223A1/en
Publication of JP2018533954A publication Critical patent/JP2018533954A/ja
Publication of JP2018533954A5 publication Critical patent/JP2018533954A5/ja
Application granted granted Critical
Publication of JP6751142B2 publication Critical patent/JP6751142B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524194A 2015-11-12 2016-11-11 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド Active JP6751142B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15194367 2015-11-12
EP15194367.7 2015-11-12
EP16189502.4 2016-09-19
EP16189502 2016-09-19
PCT/EP2016/077383 WO2017081223A1 (en) 2015-11-12 2016-11-11 Oligonucleotides for inducing paternal ube3a expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020136397A Division JP7279000B2 (ja) 2015-11-12 2020-08-12 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2018533954A JP2018533954A (ja) 2018-11-22
JP2018533954A5 true JP2018533954A5 (https=) 2020-04-09
JP6751142B2 JP6751142B2 (ja) 2020-09-02

Family

ID=57345910

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2018521350A Pending JP2018533362A (ja) 2015-11-12 2016-11-11 薬物候補の有効性プロファイルを決定するための方法
JP2018524194A Active JP6751142B2 (ja) 2015-11-12 2016-11-11 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2018521433A Expired - Fee Related JP7066609B2 (ja) 2015-11-12 2016-11-11 霊長類種に由来する標準化された神経細胞アッセイ
JP2020136397A Active JP7279000B2 (ja) 2015-11-12 2020-08-12 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2021113496A Pending JP2021191262A (ja) 2015-11-12 2021-07-08 薬物候補の有効性プロファイルを決定するための方法
JP2023009553A Pending JP2023052630A (ja) 2015-11-12 2023-01-25 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2024196762A Pending JP2025024060A (ja) 2015-11-12 2024-11-11 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018521350A Pending JP2018533362A (ja) 2015-11-12 2016-11-11 薬物候補の有効性プロファイルを決定するための方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018521433A Expired - Fee Related JP7066609B2 (ja) 2015-11-12 2016-11-11 霊長類種に由来する標準化された神経細胞アッセイ
JP2020136397A Active JP7279000B2 (ja) 2015-11-12 2020-08-12 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2021113496A Pending JP2021191262A (ja) 2015-11-12 2021-07-08 薬物候補の有効性プロファイルを決定するための方法
JP2023009553A Pending JP2023052630A (ja) 2015-11-12 2023-01-25 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2024196762A Pending JP2025024060A (ja) 2015-11-12 2024-11-11 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド

Country Status (30)

Country Link
US (10) US10494633B2 (https=)
EP (5) EP4220360B9 (https=)
JP (7) JP2018533362A (https=)
KR (4) KR102185465B1 (https=)
CN (5) CN116064539A (https=)
AU (4) AU2016352836B2 (https=)
CA (1) CA3004799C (https=)
CL (3) CL2018001189A1 (https=)
CO (1) CO2018004550A2 (https=)
CR (3) CR20220077A (https=)
DK (2) DK3374509T3 (https=)
ES (2) ES2991800T3 (https=)
FI (1) FI4220360T3 (https=)
HK (2) HK1258309A1 (https=)
HR (2) HRP20241138T1 (https=)
HU (2) HUE053197T2 (https=)
IL (4) IL300119B1 (https=)
LT (2) LT3374509T (https=)
MA (1) MA67580B1 (https=)
MX (4) MX2018004978A (https=)
PE (2) PE20210451A1 (https=)
PH (1) PH12018501005A1 (https=)
PL (2) PL4220360T3 (https=)
RS (2) RS61529B9 (https=)
RU (1) RU2742007C2 (https=)
SG (1) SG11201803951QA (https=)
SI (2) SI3374509T1 (https=)
UA (1) UA125963C2 (https=)
WO (3) WO2017081223A1 (https=)
ZA (1) ZA201802494B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
NZ714887A (en) 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
WO2014004572A2 (en) 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
LT3374509T (lt) 2015-11-12 2021-03-10 F. Hoffmann-La Roche Ag Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
KR102723989B1 (ko) 2017-12-01 2024-11-01 더 텍사스 에이 & 엠 유니버시티 시스템 엔젤만 증후군 안티센스 치료
WO2019157531A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
CN108795935B (zh) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
WO2020061528A1 (en) * 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
EP3911957A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG E3 ubiquitin ligase (ube3a) protein targets
TW202102516A (zh) * 2019-02-20 2021-01-16 丹麥商羅氏創新中心哥本哈根有限公司 膦醯基乙酸酯間隙子寡核苷酸
PT3947684T (pt) * 2019-03-29 2025-05-19 Ionis Pharmaceuticals Inc Compostos e métodos para modular ube3a‑ats
US12465655B2 (en) * 2019-05-22 2025-11-11 The University Of North Carolina At Chapel Hill UBE3A genes and expression cassettes and their use
EP3976765A1 (en) 2019-05-28 2022-04-06 F. Hoffmann-La Roche AG Method to generate monocytic progenitor cells
TW202204607A (zh) * 2020-04-16 2022-02-01 英商羅斯林科技有限公司 誘導性多功能幹細胞(iPSC)之誘導
US20230212572A1 (en) * 2020-06-09 2023-07-06 Roche Innovation Center Copenhagen A/S Guanosine Analogues for Use in Therapeutics Polynucleotides
EP4282651A4 (en) 2021-01-21 2024-12-18 Fujimori Kogyo Co., Ltd. MULTILAYER FILM AND PACKAGING BAGS
CN119173632A (zh) 2022-05-10 2024-12-20 豪夫迈·罗氏有限公司 靶向cfp-elk1基因间区域的反义寡核苷酸
EP4705457A2 (en) 2023-05-04 2026-03-11 F. Hoffmann-La Roche AG Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2025100980A1 (ko) * 2023-11-08 2025-05-15 한국과학기술원 Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도
WO2025125542A1 (en) 2023-12-15 2025-06-19 F. Hoffmann-La Roche Ag Intrathecal dosage method
WO2025213123A1 (en) * 2024-04-05 2025-10-09 Encoded Therapeutics, Inc. Methods and compositions for increasing expression of ube3a
WO2025217466A1 (en) * 2024-04-11 2025-10-16 Ultragenyx Pharmaceutical Inc. Dosing regimens for antisense treatment of angelman syndrome

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373084A (en) 1981-07-07 1983-02-08 E. I. Du Pont De Nemours And Company Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP1234174A1 (en) 1999-12-02 2002-08-28 Myriad Genetics, Inc. Protein-protein interactions
US6300132B1 (en) 1999-12-17 2001-10-09 Isis Pharmaceuticals, Inc. Antisense inhibition of telomeric repeat binding factor 2 expression
WO2001092582A1 (en) * 2000-06-01 2001-12-06 Genaissance Pharmaceuticals, Inc. Haplotypes of the ube3a gene
US20030087855A1 (en) 2001-09-13 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase R expression
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050124572A1 (en) * 2002-06-17 2005-06-09 Freier Susan M. Compositions and their uses directed to signal tranducers
WO2004016754A2 (en) 2002-08-14 2004-02-26 Pharmacia Corporation ANTISENSE MODULATION OF Nav1.3 EXPRESSION
JP2006500066A (ja) * 2002-09-25 2006-01-05 ファルマシア・コーポレーション ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節
WO2004046160A2 (en) 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
KR20060115351A (ko) * 2003-08-29 2006-11-08 위스콘신 얼럼나이 리서어치 화운데이션 영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
WO2010096496A2 (en) * 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
JP5843775B2 (ja) * 2009-10-13 2016-01-13 ステムセル テクノロジーズ インコーポレーティッド 幹細胞を分化させるための重量オスモル濃度の操作法
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
EP2595663A4 (en) 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
CA2807226A1 (en) * 2010-08-19 2012-02-23 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
US9714427B2 (en) 2010-11-11 2017-07-25 The University Of North Carolina At Chapel Hill Methods and compositions for unsilencing imprinted genes
CA2817960C (en) 2010-11-17 2020-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
DK2694644T3 (en) * 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2753631A1 (en) 2011-09-07 2014-07-16 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2014004572A2 (en) * 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014077693A1 (en) 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
ES2939807T3 (es) * 2014-03-21 2023-04-27 Fujifilm Cellular Dynamics Inc Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
LT3374509T (lt) * 2015-11-12 2021-03-10 F. Hoffmann-La Roche Ag Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
BR112019027692A2 (pt) 2017-06-28 2020-11-24 University Of South Florida gene ube3a modificado para uma abordagem terapêutica genética para a síndrome de angelman
KR102723989B1 (ko) 2017-12-01 2024-11-01 더 텍사스 에이 & 엠 유니버시티 시스템 엔젤만 증후군 안티센스 치료
AU2019212849B2 (en) 2018-01-26 2024-02-29 F. Hoffmann-La Roche Ag Radiolabelled oligonucleotides and process for their preparation
PT3947684T (pt) * 2019-03-29 2025-05-19 Ionis Pharmaceuticals Inc Compostos e métodos para modular ube3a‑ats

Similar Documents

Publication Publication Date Title
JP2018533954A5 (https=)
HRP20210227T1 (hr) Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a
MX2023010958A (es) Agentes de arn modificados con efecto reducido fuera de la diana.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
WO2013074974A3 (en) Modified rnai agents
JP2018523668A5 (https=)
BR112013010525A2 (pt) tratamento de hbv
BR112015022876A2 (pt) agente, composição farmacêutica e método para inibição da expressão do componente do complemento c5, uso do referido agente, vetor e célula.
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
MX2020005680A (es) Tratamiento antisentido del sindrome de angelman.
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
JP2016520310A5 (https=)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
JP2021500016A5 (https=)
JP2011515357A5 (https=)
WO2013162350A3 (en) Circular antiviral rna
JP2011519365A5 (https=)
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
IL274363B2 (en) Use of specific sirna against protein s for the treatment of hemophilia
RU2016141263A (ru) Аптамер для fgf2 и его применение
WO2015188198A3 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta